Results 211 to 220 of about 114,702 (262)

Leukemic penile ulcer as the presenting symptom of chronic lymphatic leukemia. [PDF]

J Surg Case Rep
Sandhu HS, Chandra S, Joshi S.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Cardiovascular Toxicities of Bruton’s Tyrosine Kinase Inhibitors

Current Treatment Options in Oncology, 2020
There has been a significant shift in the management of B cell malignancies over the past decade. Initial strategies involving the use of systemic chemotherapies have been gradually replaced by more targeted therapies to improve survival and overall tolerability.
Ricardo, Pineda-Gayoso, Mohammed, Alomar, Dae Hyun, Lee, Michael G, Fradley   +3 more
openaire   +2 more sources

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765)

Leukemia & Lymphoma, 2013
Over the past 3 years, ibrutinib (PCI-32765) has emerged as a breakthrough in targeted therapy for patients with certain types of B cell malignancies. Early stage clinical trials found ibrutinib to be particularly active in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), providing the rationale for ongoing phase 3 trials. In contrast
Jan A, Burger, Joseph J, Buggy
openaire   +2 more sources

Bruton's tyrosine kinase inhibitors

Current Opinion in Oncology, 2014
Targeted inhibitors of B-cell receptor signaling have emerged as the most promising therapeutic options against non-Hodgkin's lymphoma. The inhibitor agents that target Bruton's tyrosine kinase (BTK) have elicited particularly high enthusiasm given the unprecedented positive responses observed in Phase I trials.
Loic, Ysebaert, Anne-Sophie, Michallet
openaire   +2 more sources

Bayesian machine learning to discover Bruton’s tyrosine kinase inhibitors

Chemical Biology & Drug Design, 2020
AbstractBruton's tyrosine kinase (BTK) has a crucial role in multiple cell signaling pathways including B‐cell antigen receptor (BCR) and Fc receptor (FcR) signaling cascades, which has attracted much attention to find BTK inhibitors to treat autoimmune diseases.
Jian Wang, Ting Ran, Yadong Chen, Tao Lu
openaire   +2 more sources

Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one, by Fragment-Based Drug Design.

Journal of Medicinal Chemistry, 2021
This publication details the successful use of FBDD (fragment-based drug discovery) principles in the invention of a novel covalent Bruton's tyrosine kinase inhibitor, which ultimately became the Takeda Pharmaceuticals clinical candidate TAK-020 ...
Mark Sabat, D. Dougan, B. Knight, J. Lawson, N. Scorah, Christopher R. Smith, E. Taylor, Phong H. Vu, C. Wyrick, Haixia Wang, Deepika Balakrishna, M. Hixon, L. Madakamutil, D. McConn   +13 more
semanticscholar   +1 more source

Acalabrutinib, A Second-Generation Bruton’s Tyrosine Kinase Inhibitor

2018
The Bruton's tyrosine kinase (BTK) is an essential in the B-cell receptor (BCR) signaling pathway which was identified as crucial in the pathogenesis of B-cell malignancies. Ibrutinib, a first-in-class BTK inhibitor, has been approved for the treatment of distinct B-cell malignancies.
Katharina, Kriegsmann, Mark, Kriegsmann, Mathias, Witzens-Harig   +2 more
openaire   +2 more sources

Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors

Leukemia & Lymphoma, 2017
The development of bruton tyrosine kinase inhibitors (BTKi) has been a significant advancement in the treatment of chronic lymphocytic leukemia and related B-cell malignancies. As experience in using ibrutinib increased, the first drug to be licensed in its class, atrial fibrillation (AF) emerged as an important side effect.
Chloe Pek Sang, Tang, Julie, McMullen, Constantine, Tam   +2 more
openaire   +2 more sources

Arrhythmia in Bruton Tyrosine Kinase Inhibitor-Treated Patients: Unanswered Questions

Chemotherapy, 2023
(No abstract allowed for commentary)
Michael S. Ewer, Steven M. Ewer
openaire   +2 more sources

Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia: A review

Journal of Oncology Pharmacy Practice, 2021
Objective The objective of this review is to evaluate the available evidence for the Bruton tyrosine kinase inhibitors in the treatment of Waldenström macroglobulinemia. Data sources A search of the PubMed database was conducted using the following search terms: ibrutinib, PCI-32765, acalabrutinib, ACP-196, zanubrutinib, BGB-3111, and Waldenström ...
openaire   +2 more sources